Last €34.49 EUR
Change Today +0.475 / 1.40%
Volume 975.0
NOVA On Other Exchanges
Symbol
Exchange
OTC US
Copenhagen
New York
Frankfurt
Frankfurt
As of 12:13 PM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

novo-nordisk a/s-spons adr (NOVA) Snapshot

Open
€33.28
Previous Close
€34.02
Day High
€34.49
Day Low
€33.28
52 Week High
02/26/14 - €35.57
52 Week Low
10/9/13 - €23.94
Market Cap
91.4B
Average Volume 10 Days
1.6K
EPS TTM
--
Shares Outstanding
2.1B
EX-Date
03/21/14
P/E TM
--
Dividend
€0.81
Dividend Yield
1.75%
Current Stock Chart for NOVO-NORDISK A/S-SPONS ADR (NOVA)

Related News

No related news articles were found.

novo-nordisk a/s-spons adr (NOVA) Details

Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes Care segment covers insulins, GLP-1 analog, obesity, and oral antidiabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth hormone therapy, hormone replacement therapy, and inflammation. The company sells its products primarily in North America, China, Japan, Algeria, Argentina, Australia, Brazil, India, Turkey, and European countries through its subsidiaries, distributors, and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

39,579 Employees
Last Reported Date: 05/1/14
Founded in 1925

novo-nordisk a/s-spons adr (NOVA) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: kr15.2M
President and Chief Operating Officer
Total Annual Compensation: kr9.0M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: kr8.1M
Chief Science Officer and Executive Vice Pres...
Total Annual Compensation: kr8.1M
Chief of Staff and Executive Vice President
Total Annual Compensation: kr7.0M
Compensation as of Fiscal Year 2013.

novo-nordisk a/s-spons adr (NOVA) Key Developments

Novo Nordisk A/S Announces Positive Data from Phase IIIa Obesity and Diabetes Study

Novo Nordisk A/S has announced data from SCALE Diabetes, a Phase IIIa clinical trial of liraglutide 3mg, which demonstrated statistically significant weight loss at 56 weeks in adults with obesity and type 2 diabetes or who were overweight with type 2 diabetes, compared with placebo. All treatment groups included a reduced-calorie diet and increased physical activity. At 56 weeks of treatment, the SCALE Diabetes trial showed that adults treated with liraglutide 3 mg achieved significantly greater mean weight loss of 5.9% of baseline body weight compared with 4.6% with liraglutide 1.8 mg compared with placebo (-1.1% vs. -0.4%, P<0.0001) and statistically more people achieved HbA1c target (<7%) with liraglutide 1.8 mg compared with placebo (69.6% vs. 22.9%, P<0.0001). The most frequently reported side effects were gastrointestinal disorders (driven by nausea and diarrhoea), and occurred in 65% of people treated with liraglutide 3 mg compared with 56% with liraglutide 1.8 mg and 39% with placebo. The most common adverse events occurring in more than 5% of people treated with liraglutide 3 mg included hypoglycaemia, decreased appetite, abdominal distension, abdominal pain, dyspepsia, flatulence, vomiting, constipation, nasopharyngitis, usually referred to as the common cold, upper respiratory tract infection, influenza, back pain, musculoskeletal pain, arthralgia, headache, dizziness, fatigue and increased lipase. The most frequent side effects leading to withdrawal from the liraglutide 3 mg treatment group were gastrointestinal disorders (5.7%). Liraglutide is currently available in the US and other countries at lower doses under the brand name Victoza for treatment of adults with type 2 diabetes mellitus to improve blood glucose control. FDA guidance recommends that any investigational product being developed for weight management should be investigated in people with type 2 diabetes, as overweight and obese patients with type 2 diabetes often respond less favourably to weight-management medications. The FDA requested the inclusion of liraglutide 1.8 mg (Victoza) in the SCALE Diabetes study to bridge to the safety and efficacy data for Victoza in the treatment of adults with type 2 diabetes. Liraglutide 3 mg is a once-daily glucagon-like peptide-1 (GLP-1) analogue with 97% similarity to naturally occurring human GLP-1,4 a hormone that is released in response to food intake.

Novo Nordisk Announces the Availability of it's Levemir(R) FlexTouch(R) in the United States

Novo Nordisk announced the availability of it's new prefilled insulin delivery device Levemir(R) FlexTouch(R) (insulin detemir [rDNA origin] injection) in the United States. This device represents an advancement in insulin delivery and is based on years of feedback from endocrinologists, certified diabetes educators, primary care physicians and other health care professionals, providing a new way patients with diabetes can administer their insulin. When a dose is dialed with traditional prefilled insulin pens, the push button extends, and at larger doses this may present delivery challenges for the patient. Levemir(R) FlexTouch(R) is the first and only prefilled insulin delivery device with no push-button extension. Due to the unique dosing mechanism of FlexTouch(R), the push button does not extend at any dose and allows insulin to be administered by pressing the low injection force button. Levemir(R) FlexTouch(R) is available on more than 96% of Commercial and Medicare Part D plans nationwide, including exclusive Tier 1 status on United Health care and preferred status on Coventry.

Novo Nordisk Presents at IP Business Congress Global 2014 Conference, Jun-23-2014 02:05 PM

Novo Nordisk Presents at IP Business Congress Global 2014 Conference, Jun-23-2014 02:05 PM. Venue: Amsterdam, Netherlands. Speakers: Reza Green, Vice President of IP.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NOVA:GR €34.49 EUR +0.475

NOVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $54.16 USD +0.11
Amgen Inc $121.36 USD +0.25
AstraZeneca PLC 4,421 GBp -5.00
Bristol-Myers Squibb Co $49.05 USD -0.07
Eli Lilly & Co $64.34 USD +0.62
View Industry Companies
 

Industry Analysis

NOVA

Industry Average

Valuation NOVA Industry Range
Price/Earnings 26.2x
Price/Sales 7.9x
Price/Book 19.7x
Price/Cash Flow 20.6x
TEV/Sales 6.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVO-NORDISK A/S-SPONS ADR, please visit www.novonordisk.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.